Could new cancer targets change the outlook for personalised medicine? Kathleen Pritchard
Personalised medicine and the future of oncology treatment Gerd Munzert
Personalising cancer care and the future of cancer treatments John Heymach
Afatinib* (compound code BIBW 2992) Mode of Action
Changing the outlook for personalised cancer therapy Boehringer Ingelheim
Targeted cancer therapies
ErbB-Family Blockade and afatinib*
Afatinib* Backgrounder
Boehringer Ingelheim and the search for new targeted cancer treatments
Irreversible binding of afatinib
Afatinib (BIBW 2992) slide kit
Mode of action afatinib* slide kit
Could new cancer targets change the outlook for personalised medicine?
Webcast South Korea, the evolution of lung cancer care
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.